On October 1, 2024, Rosty Raykov, a Director at Fennec Pharmaceuticals Inc (FENC, Financial), sold 2,431 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 66,432 shares of Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a biopharmaceutical company focused on the development of PEDMARKâ„¢, a unique formulation of sodium thiosulfate designed to reduce the incidence of hearing loss in pediatric cancer patients receiving platinum-based chemotherapy.
Over the past year, Rosty Raykov has sold a total of 172,453 shares and has not purchased any shares. This recent transaction continues a trend observed over the last year, where there have been 21 insider sells and no insider buys at Fennec Pharmaceuticals Inc.
Shares of Fennec Pharmaceuticals Inc were trading at $4.94 on the day of the sale, giving the company a market cap of $130.159 million. The price-earnings ratio of the stock stands at 120.50, which is above the industry median of 27.77.
For more detailed valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow, investors may refer to the GF Value of the stock.
This insider sale might be of interest to investors tracking insider behaviors and the overall trading patterns within Fennec Pharmaceuticals Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
